GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ivonescimab   Click here for help

GtoPdb Ligand ID: 13396

Synonyms: AK-112 | AK112 | Idafang® (China) | SMT-112 | SMT112
Approved drug Immunopharmacology Ligand
ivonescimab is an approved drug (China (2024))
Compound class: Antibody
Comment: Ivonescimab (AK112/SMT112) is a first-in-class anti-programmed death-1 (PD-1)/VEGF-A bispecific monoclonal antibody. It was designed to simultaneously block both PD-1 and VEGF-mediated immunosuppression in the tumour microenvironment (TME) and inhibit the pro-angiogenic action of VEGF. Interaction of ivonescimab with VEGF-A increases the antibody's avidity for PD-1 and enhances the inhibitory effect on PD-1/PD-L1 signalling [5].
Immunopharmacology Comments
Ivonescimab is designed to block the immunosuppressive effects of both PD-1 and VEGF in the TME.